Lindsay joined Canaan Partners in 2011 as an Investment Analyst on the Healthcare team. Prior to joining Canaan, Lindsay was a Senior Consultant at Deloitte Recap LLC. At Recap, Lindsay analyzed trends in alliance formation and licensing, assisted with the firms expert witness testimony, and worked on consulting projects for biopharmaceutical clients. Prior to Recap, Lindsay was an Analyst at CV Therapeutics (CVT), a cardiovascular drug company located in Palo Alto. At CVT, Lindsay was responsible for the company’s investor relations activities and supported the senior management team in a variety of strategic initiatives including a $385M European licensing agreement, a $185M royalty financing, and the company’s $1.4B sale to Gilead Sciences in April 2009. Lindsay also worked in corporate finance at Amgen, Inc. and in investment management at Goldman, Sachs & Co.
An alumnus of the University of Notre Dame, Lindsay has a BS in Science-Business and served as president of the student-management investment fund.